Preclinical data highlights the potential of
engineered macrophage cell therapy as a treatment for liver and
lung fibrosis
Novel Redirected Soluble Modulator technology
has demonstrated the potential to enhance immune receptor
signaling
PHILADELPHIA, April 22,
2024 /PRNewswire/ -- Carisma Therapeutics
Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a
clinical-stage biopharmaceutical company focused on discovering and
developing innovative immunotherapies, today announced the
acceptance of two abstracts at the American Society of Gene and
Cell Therapy (ASGCT) 2024 Annual Meeting being held May 7-11, 2024, in Baltimore, MD.
"We are excited to present new preclinical data highlighting the
potential of our engineered macrophage cell therapies for the
treatment of liver and lung fibrosis, both of which represent
significant unmet medical needs with limited available therapies
for patients," said Michael
Klichinsky, PharmD, PhD, Co-founder and Chief Scientific
Officer of Carisma. "We look forward to presenting these data and
are excited to expand our macrophage engineering platform beyond
oncology."
Poster Presentation Details:
Title: Genetically Engineered Macrophage Cell Therapy
Reverses Liver and Lung Fibrosis in Preclinical Models
Abstract #: 852
Session: Other Cellular and Regenerative Therapies
Date & Time: Wednesday, May 8,
2024; 12:00 PM ET
Location: Exhibit Hall
Title: Redirected Soluble Modulators (RSM) – A Novel
Engineering Strategy to Enhance Immune Receptor Signaling
Abstract #: 812
Session: Immune Targeting and Approaches with
Genetically-Modified Cells and Cell Therapies
Date & Time: Wednesday, May 8,
2024; 12:00 PM ET
Location: Exhibit Hall
The posters presented at ASGCT 2024 will be available online in
the "Publications" section of Carisma's website at
https://carismatx.com/technology/publications/ following the
start of the respective poster sessions.
About Carisma
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Cautionary Note on Forward-Looking
Statements
Statements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
"forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to Carisma's business,
strategy, future operations, cash runway, the advancement of
Carisma's product candidates and product pipeline, and clinical
development of Carisma's product candidates, including expectations
regarding timing of initiation and results of clinical trials. The
words "anticipate," "believe," "contemplate," "continue," "could,"
"estimate," "expect," "goals," "intend," "may," "might," "outlook,"
"plan," "project," "potential," "predict," "target," "possible,"
"will," "would," "could," "should," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Any forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. These risks and uncertainties
include, but are not limited to, (i) Carisma's ability to obtain,
maintain and protect its intellectual property rights related to
its product candidates; (ii) Carisma's ability to advance the
development of its product candidates under the timelines it
anticipates in planned and future clinical trials and with its
current financial and human resources; (iii) Carisma's ability to
replicate in later clinical trials positive results found in
preclinical studies and early-stage clinical trials of its product
candidates; (iv) Carisma's ability to realize the anticipated
benefits of its research and development programs, strategic
partnerships, research and licensing programs and academic and
other collaborations; (v) regulatory requirements or developments
and Carisma's ability to obtain and maintain necessary approvals
from the U.S. Food and Drug Administration and other regulatory
authorities related to its product candidates; (vi) changes to
clinical trial designs and regulatory pathways; (vii) risks
associated with Carisma's ability to manage expenses; (viii)
changes in capital resource requirements; (ix) risks related to the
inability of Carisma to obtain sufficient additional capital to
continue to advance its product candidates and its preclinical
programs; and (x) legislative, regulatory, political and economic
developments.
For a discussion of these risks and uncertainties, and other
important factors, any of which could cause Carisma's actual
results to differ from those contained in the forward-looking
statements, see the "Risk Factors" set forth in the Company's
Annual Report on Form 10-K for the year ended December 31, 2023, as well as discussions of
potential risks, uncertainties, and other important factors in
Carisma's other recent filings with the Securities and Exchange
Commission. Any forward-looking statements that are made in this
press release speak as of the date of this press release. Carisma
undertakes no obligation to revise the forward-looking statements
or to update them to reflect events or circumstances occurring
after the date of this press release, whether as a result of new
information, future developments or otherwise, except as required
by the federal securities laws.
Investors:
Shveta
Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-new-data-at-the-american-society-of-gene-and-cell-therapy-asgct-annual-meeting-302123620.html
SOURCE Carisma Therapeutics Inc.